Lesinurad
Lesinurad is an inhibitor of URAT1 that promoting renal uric acid excretion [1].URAT1 is a transporter in the kidney that regulates uric acid excretion from the body [2].
In the clinical study, lesinurad potently inhibit URAT1 as well as OAT4, another transporter responsible for the renal resorption of urate. In a study, 21 people with hyperuricemia or gout (sUA >= 8.0 mg/dL) were randomized to lesinurad, open-label allopurinol or placebo. Most of the lesinurad-treated patients had sUA < 6 mg/dL after seven days, which were the same effect to patients receiving allopurinol and better than placebo. Also, Lesinurad showed well tolerated in the study [2]. Compared with probenecid, whose efficacy is reducing patients with renal insufficiency, lesinurad may be effective in patients with mildly impaired renal function [1].
References:
[1]. Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med, 2013, 64: 325-337.
[2]. Singh JA. Emerging therapies for gout. Expert Opin Emerg Drugs, 2012, 17(4): 511-518.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 404.28 |
| Cas No. | 878672-00-5 |
| Formula | C17H14BrN3O2S |
| Synonyms | RDEA 594;RDEA-594;RDEA594 |
| Solubility | insoluble in H2O; ≥40.9 mg/mL in EtOH with ultrasonic; ≥92.2 mg/mL in DMSO with ultrasonic |
| Chemical Name | 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid |
| SDF | Download SDF |
| Canonical SMILES | O=C(O)CSC1=NN=C(Br)N1C2=C3C(C=CC=C3)=C(C4CC4)C=C2 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
